Home Featured Page 149

Featured

Latest

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Q3’25 Investor Survey: What are Investors Most Concerned About?

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic...

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction...

Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

GH Research Reports Second Quarter 2022 Financial Results and Provides Business...

PT349 – Brenna Gebauer – Slowing Down, The Ethics of Touch,...

Opinions | The Psychedelic Community Takes Itself Too Seriously

Algernon Pharmaceuticals Announces Private Placement

Issues of Patient Safety and Ethical Violations in Psychedelic Therapy

Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains...

1...148149150...300 Page 149 of 300

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Q3’25 Investor Survey: What are Investors Most Concerned About?

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic...

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction...

Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

GH Research Reports Second Quarter 2022 Financial Results and Provides Business...

PT349 – Brenna Gebauer – Slowing Down, The Ethics of Touch,...

Interview | Josh Ismin, Psylo

Opinions | The Psychedelic Community Takes Itself Too Seriously

Algernon Pharmaceuticals Announces Private Placement

Issues of Patient Safety and Ethical Violations in Psychedelic Therapy

Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains...

EDITOR PICKS

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY